NEURONASAL INC
Intranasal N-acetylcysteine (NAC) delivery system for nose-to-brain transport to treat Parkinson's Disease
- Sector
- Biotech
- Total capital
- $478K
- Federal grants
- $478K
- 1 award · 2024
- Rank in peer group#284 of 502
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 11 pending · first 2026
- Rank in peer group#41 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Circumventing the pharmacokinetic/pharmacodynamic limitations of antioxidant therapy for Parkinson's Disease by nose to brain delivery of N-acetylcysteine$478K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#41 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 2 granted of 13- PendingTreatment Of Central Nervous System Diseases With N-acetylcysteine And Glucagon-like PEPTIDE-1 Receptor AgonistsUSPTOApplication 19418017
- GrantedMethods Of Administering Glutathione PrecursorsUSPTOUS 12,648,920
- GrantedIntranasal Administration Of N-acetylcysteine And Uses ThereofUSPTOUS 12,594,254
Show all 13 patent records
- Treatment Of Central Nervous System Diseases With N-acetylcysteine And Glucagon-like PEPTIDE-1 Receptor AgonistsJun 18, 2026 · Application 19418017Pending
- Methods Of Administering Glutathione PrecursorsJun 9, 2026 · US 12,648,920Granted
- Intranasal Administration Of N-acetylcysteine And Uses ThereofApr 7, 2026 · US 12,594,254Granted
- Magnetic Resonance Spectroscopy To Calibrate And Select Doses, Formulations, And Devices For Intra-nasal Administration Of N-acetylcysteineOct 12, 2023 · Application 18295125Pending
- Use Of Magnetic Resonance Spectroscopy To Calibrate And Select Doses, Formulations, And Devices For Intra-nasal Administration Of N-acetylcysteineMay 6, 2021 · Application 17089192Pending
- Use Of Magnetic Resonance Spectroscopy To Calibrate And Select Doses, Formulations, And Devices For Intra-nasal Administration Of N-acetylcysteineApplication PCTUS2020058905Pending
- Methods Of Delivering N-acetylcysteine, N-acetylcysteine Derivatives, Or N-acetylcysteine Congeners To Treat Brain DisordersApplication 62970254Pending
- Intranasal Administration Of N-acetylcysteine And Uses ThereofApplication 63307260Pending
- Methods Of Delivering N-acetylcysteine To Treat Brain DisordersApplication 62949640Pending
- Treatment Of Central Nervous System Diseases With N-acetylcysteine And Glucagon-like PEPTIDE-1 Receptor AgonistsApplication PCTUS2025059398Pending
- Intranasal Administration Of N-acetylcysteine And Uses ThereofApplication PCTUS2023012538Pending
- Methods Of Administering Glutathione PrecursorsApplication PCTUS2021046992Pending
- Methods Of Administering N-acetylcysteineApplication 63116404Pending
Related companies, and why
- ELIXIRGEN, LLCSimilar federal contract value in Biotech · null in contracts
- TERNALYS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- Gateway Bio, Inc.Similar federal contract value in Biotech · null in contracts
- EtiomeSimilar federal contract value in Biotech · null in contracts
- TEMPRIAN ONCOLOGY, INC.Similar federal contract value in Biotech · null in contracts
- Vividion TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .